New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
04:55 EDTBAX, BAX, BAX, LH, LH, LH, ACT, ACT, ACT, HUM, HUM, HUM, UNH, UNH, UNH, THOR, THOR, THOR, HSIC, HSIC, HSIC, VRTX, VRTX, VRTX, CNC, CNC, CNC, BSX, BSX, BSX, HNT, HNT, HNTBarclays to hold a conference
Healthcare Conference is being held in Miami, Florida on March 11-13.
News For BAX;BSX;CNC;VRTX;HSIC;THOR;UNH;HUM;ACT;LH;HNT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
June 23, 2015
09:45 EDTHUMAnthem concerned Cigna may bid for Humana, CNBC's Faber reports
Subscribe for More Information
08:09 EDTHSICHenry Schein to acquire majority interest in Jorgen Kruuse A/S
Subscribe for More Information
07:44 EDTHUMHumana takeover looks unlikely below $210/share, says Leerink
Subscribe for More Information
07:25 EDTBSX, LH, UNH, HSICPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
06:00 EDTHUMHumana implied volatility of 48 at upper end of index
June 22, 2015
18:56 EDTHUMCigna/Anthem deal could leave Humana with Aetna as only suitor, Bloomberg says
Subscribe for More Information
09:04 EDTBSXBoston Scientific initiates study to assess EMBLEM S-ICD
Subscribe for More Information
08:16 EDTHUMAnthem, Cigna deal would be negative for Catamaran, says Leerink
Subscribe for More Information
07:54 EDTHUMAnthem, Cigna deal likely to be consummated, says Leerink
Subscribe for More Information
07:16 EDTHUMAnthem should be bought after Cigna offer, says Stifel
After Anthem, (ANTM) offered to buy Cigna (CI) and the latter company rejected the bid, Stifel estimates that the deal would have been 10% accretive for Anthem in the first year and 20% accretive in the second year. The firm thinks that accretion from the deal will probably be higher than expected. It also recommends buying Aetna (AET) as it believes that the Anthem offer suggests that Aetna will benefit more than expected from its own deal. The firm is cautious on Humana (HUM), saying that it may lose two potential buyers in Anthem and Cigna, while Humana may retreat if Aetna does not acquire the company quickly.
06:51 EDTUNH, HUMHealth insurer tie-ups could cut competition, WSJ reports
Subscribe for More Information
06:37 EDTHNT, CNC, HUM, UNHHealth insurers may change policies based on King v. Burwell ruling, NYT says
Subscribe for More Information
06:32 EDTBAXKamada collaborates with Baxter on clinical trial with Alpha-1 antitrypsin
Kamada (KMDA) reports that the company has entered into a collaboration with Baxalta International, a wholly-owned subsidiary of Baxter (BAX) on a Phase 1/2 clinical trial of Kamada’s proprietary alpha-1 antitrypsin treatment for the prevention of lung transplant rejection. Under the agreement, Baxalta will collaborate in the development and funding of the study, which will be conducted in Israel. The study is expected to initiate in the first half of 2016, with more details on trial design to be provided at a later date. Kamada’s proprietary, highly-purified, liquid form of human AAT has shown positive interim results in a proof-of-concept Phase II study in Graft-versus-Host-Disease conducted at the Fred Hutchinson Cancer Research Center in cooperation with Baxalta. Based on those results, preclinical data published in Blood, and at the American Society of Hematology meeting, and a similar mechanism of action, the companies now plan to expand the AAT indication to the prevention of lung transplant rejection and may use this data to support clinical development worldwide. Baxalta has distribution rights to intravenous AAT for all indications in the U.S., Canada, Australia and New Zealand, while Kamada has rights in all other territories and all other formulations.
June 21, 2015
16:03 EDTUNH, HUMAetna makes offer to acquire Humana, WSJ says
Subscribe for More Information
June 19, 2015
18:12 EDTBAXS&P announces changes to S&P 100, 400, 500, and 600 indices
S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices: S&P 500 constituent The Priceline Group (PCLN) will replace Baxter International (BAX) in the S&P 100, Baxalta (BXLT) will replace QEP Resources (QEP) in the S&P 500, QEP Resources will replace Itron (ITRI) in the S&P MidCap 400, and Itron will replace Arch Coal (ACI) in the S&P SmallCap 600 after the close of trading on Tuesday, June 30. Baxter International is spinning off Baxalta in a transaction expected to be completed on that date. Baxter International will remain in the S&P 500 following the distribution, but its post spin market capitalization will no longer make it appropriate for the S&P 100. QEP Resources, Itron and Arch Coal are all ranked near or at the bottom of their current indices. Skechers USA (SKX) will replace Rock-Tenn Co. (RKT) in the S&P MidCap 400, and MiMedx Group (MDXG) will replace Skechers USA in the S&P SmallCap 600 after the close of trading on Tuesday, June 30. S&P 500 constituent MeadWestvaco Corp. (MWV) is combining with Rock-Tenn in a transaction expected to be completed on or about that date. The combined company will remain in the S&P 500 and will change its name to WestRock Co. HealthEquity (HQY) will replace Zep Inc. (ZEP) in the S&P SmallCap 600 after the close of trading on Thursday, June 25. Private equity firm New Mountain Capital is acquiring Zep in a transaction expected to be completed on or about that date pending final approvals.
17:19 EDTBAXPriceline to replace Baxter in S&P 100 as of 6/30 close
Subscribe for More Information
16:24 EDTUNH, HUMStocks end week higher after Fed reassures on gradual pace of rate increases
Subscribe for More Information
10:09 EDTCNC, HUM, HNT, UNHFly Watch: Supreme Court may release key ACA decision soon
Subscribe for More Information
09:18 EDTHUMHumana most likely target in Managed Care, says FBR Capital
FBR Capital says Humana (HUM) is the most likely acquisition target in the Managed Care space, with Aetna (AET), Anthem (ANTM) and Cigna (CI) as the likely acquirers. The firm believes Anthem would benefit the most from the acquisition of Humana. It also thinks UnitedHealth (UNH) could look to acquire Aetna or Cigna. FBR thinks one or two more large deals in the space are possible.
07:37 EDTHUM, UNHSupreme Court decision on ACA suit due soon, says UBS
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use